Business
AstraZeneca to run fresh COVID-19 vaccine trial amid results confusion – The Australian Financial Review
AstraZeneca and its CEO are facing scrutiny as the drugmaker responds to growing confusion over the vaccine.
AstraZeneca and its partner, the University of Oxford, reported on Monday that a lower initial dose of the vaccine, followed by a full dose, produced a 90 per cent efficacy rate, compared with 62 per cent for two full doses.
A day after the data were unveiled the head of the US vaccine program known as Operation Warp Speed said that the regimen showing the higher level of effectiveness was tested in a younger population. He also said that the half-dose was given to some people because of an error…
-
General24 hours agoTwo men involved in fatal helicopter accident charged over stealing crocodile eggs from Kakadu National Park
-
Noosa News14 hours agoInquest into Rosemarie Campbell’s death three days after gastric bypass surgery hears of ‘massive loss’ to family
-
Noosa News6 hours agoReubhan Ralph identified as man behind terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
General12 hours agoQueensland announced as 2027 Women’s Softball World Cup host in first Australian event since 1965